The medication, suzetrigine, has been developed by Vertex, and has been approved for moderate to severe acute pain. It works by inhibiting voltage-gated sodium channel 1.8 (NaV1.8), which is involved in pain transmission. Unlike other sodium channel blockers, such as local anesthetics, the medication does not affect sensory and motor function.